Cite
HARVARD Citation
Ullrich, N. et al. (2020). A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro-oncology. 22 (10), pp. 1527-1535. [Online].